CETUS, DU PONT SETTLE PCR DISPUTE

Cetus Corp. and Du Pont said Friday that they have settledlitigation regarding Cetus' polymerase chain reactiontechnology.

The settlement includes dismissal of the pending federal courtcases. Du Pont and Cetus, now a subsidiary of Chiron Corp.,declined to say whether any payment or technology exchangehad been made.

Du Pont sued Cetus in 1989, claiming its patents were invalidbased on prior art. A jury in February upheld the validity oftwo of Cetus' PCR patents. A second trial had been planned todetermine whether Du Pont had infringed Cetus' patents and todetermine damages.

Cetus sold the PCR technology last week to F. Hoffmann-LaRoche Inc. as part of the Chiron merger. Chiron stock(NASDAQ:CHIR) closed at $63.50 on Friday, down 38 cents.

(c) 1997 American Health Consultants. All rights reserved.